

# Ccr2-IRES-DTRGFP

<b>Nomenclature</b>	C57BL/6Smoc- <i>Ccr2</i> <sup>em1(IRES-DTRGFP)Smoc</sup>
<b>Cat. NO.</b>	NM-KI-210102
<b>Strain State</b>	Repository Live

## Gene Summary

<b>Gene Symbol</b> Ccr2	<b>Synonyms</b>	Ckr2; Ccr2a; Ccr2b; Ckr2a; Ckr2b; mJe-r; Cmkbr2; Cc-ckr-2
	<b>NCBI ID</b>	<a href="#">12772</a>
	<b>MGI ID</b>	<a href="#">106185</a>
	<b>Ensembl ID</b>	<a href="#">ENSMUSG00000049103</a>
	<b>Human Ortholog</b>	CCR2

## Model Description

IRES-DTRGFP expression cassette was knocked into the Ccr2 gene .

\*Literature published using this strain should indicate: Ccr2-IRES-DTRGFP mice (Cat. NO. NM-KI-210102) were purchased from Shanghai Model Organisms Center, Inc..

## Validation Data




Fig1. Analysis of GFP expression in the *Ccr2*-IRES-DTRGFP mice by FACS. The expression of GFP could be detected in CCR2+ and CD11b+ cells in peripheral blood of the heterozygous KI mice.

### Schematic diagram of DT dosing and FACS analysis time points:




Fig2. Analysis of CCR2+/CD11b+ cells proportion and GFP level in Ccr2-IRES-DTRGFP mice by FACS. The heterozygous KI mice were treated with DT (qd x 3 days). After 2 days of drug withdrawal, the proportion of CCR2+ and CD11b+ cells in the peripheral blood were decreased, and the level of GFP positive cells also decreased. After 4 days of drug withdrawal, the proportion of CCR2+ and CD11b+ cells returned to normal, and the level of GFP positive cells also returned to normal.